These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 25714671)

  • 1. Liver protein profiles in insulin receptor-knockout mice reveal novel molecules involved in the diabetes pathophysiology.
    Capuani B; Della-Morte D; Donadel G; Caratelli S; Bova L; Pastore D; De Canio M; D'Aguanno S; Coppola A; Pacifici F; Arriga R; Bellia A; Ferrelli F; Tesauro M; Federici M; Neri A; Bernardini S; Sbraccia P; Di Daniele N; Sconocchia G; Orlandi A; Urbani A; Lauro D
    Am J Physiol Endocrinol Metab; 2015 May; 308(9):E744-55. PubMed ID: 25714671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic and bioinformatic analysis of membrane proteome in type 2 diabetic mouse liver.
    Kim GH; Park EC; Yun SH; Hong Y; Lee DG; Shin EY; Jung J; Kim YH; Lee KB; Jang IS; Lee ZW; Chung YH; Choi JS; Cheong C; Kim S; Kim SI
    Proteomics; 2013 Apr; 13(7):1164-79. PubMed ID: 23349036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity.
    Kubota N; Kubota T; Kajiwara E; Iwamura T; Kumagai H; Watanabe T; Inoue M; Takamoto I; Sasako T; Kumagai K; Kohjima M; Nakamuta M; Moroi M; Sugi K; Noda T; Terauchi Y; Ueki K; Kadowaki T
    Nat Commun; 2016 Oct; 7():12977. PubMed ID: 27708333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
    Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
    J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.
    Qin B; Anderson RA; Kuzuya T; Kitaura Y; Shimomura Y
    Atherosclerosis; 2012 Jun; 222(2):409-16. PubMed ID: 22546076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracting time-dependent obese-diabetic specific networks in hepatic proteome analysis.
    Midha MK; Tikoo K; Sinha N; Kaur S; Verma HN; Rao KV; Chatterjee S; Manivel V
    J Proteome Res; 2012 Dec; 11(12):6030-43. PubMed ID: 23050596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2.
    Kido Y; Burks DJ; Withers D; Bruning JC; Kahn CR; White MF; Accili D
    J Clin Invest; 2000 Jan; 105(2):199-205. PubMed ID: 10642598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved metabolic disorders of insulin receptor-deficient mice by transgenic overexpression of glucokinase in the liver.
    Jackerott M; Baudry A; Bucchini D; Jami J; Joshi RL
    Diabetologia; 2002 Sep; 45(9):1292-7. PubMed ID: 12242462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis of propiconazole responses in mouse liver: comparison of genomic and proteomic profiles.
    Ortiz PA; Bruno ME; Moore T; Nesnow S; Winnik W; Ge Y
    J Proteome Res; 2010 Mar; 9(3):1268-78. PubMed ID: 20095644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
    Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
    Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
    Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
    Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
    Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice.
    Barbosa-da-Silva S; Souza-Mello V; Magliano DC; Marinho Tde S; Aguila MB; Mandarim-de-Lacerda CA
    Life Sci; 2015 Apr; 127():73-81. PubMed ID: 25748419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fibroblast growth factor 19 in the control of glucose homeostasis.
    Schaap FG
    Curr Opin Clin Nutr Metab Care; 2012 Jul; 15(4):386-91. PubMed ID: 22617565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteome analysis of fatty liver in feed-deprived dairy cows reveals interaction of fuel sensing, calcium, fatty acid, and glycogen metabolism.
    Kuhla B; Albrecht D; Kuhla S; Metges CC
    Physiol Genomics; 2009 Apr; 37(2):88-98. PubMed ID: 19240300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.
    Kim MH; Park JS; Jung JW; Byun KW; Kang KS; Lee YS
    Int J Obes (Lond); 2011 Aug; 35(8):1019-30. PubMed ID: 21157426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered insulin receptor messenger ribonucleic acid splicing in liver is associated with deterioration of glucose tolerance in the spontaneously obese and diabetic rhesus monkey: analysis of controversy between monkey and human studies.
    Huang Z; Bodkin NL; Ortmeyer HK; Zenilman ME; Webster NJ; Hansen BC; Shuldiner AR
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1552-6. PubMed ID: 8636366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.